Marc Larkins Portfolio
Invests via Johnson & Johnson | Managed by Marc Larkins
Invests via Johnson & Johnson
Managed by Marc Larkins
Automatically Tracked
Marc Larkins Profile
Marc Larkins is a seasoned entrepreneur known for his innovative approach in the tech sector. With an impressive track record of launching successful startups, he has consistently driven growth through strategic vision and execution. His background spans engineering and business management, allowing him to blend technical expertise with market insights effectively. Larkins has cultivated a reputation as a thought leader within the entrepreneurial community, fostering collaboration among emerging companies and established industry players alike. His ability to identify unique market opportunities positions him as a significant influencer in technology commercialization.
Marc Larkins is a seasoned entrepreneur known for his innovative approach in the tech sector. With an impressive track record of launching successful startups, he has consistently driven growth through strategic vision and execution. His background spans engineering and business management, allowing him to blend technical expertise with market insights effectively. Larkins has cultivated a reputation as a thought leader within the entrepreneurial community, fostering collaboration among emerging companies and established industry players alike. His ability to identify unique market opportunities positions him as a significant influencer in technology commercialization.
Investment Philosophy & Strategy
Opportunity identification is at the core of Marc Larkins' investment philosophy, driven by a deep understanding of technology and market dynamics. His entrepreneurial journey informs a proactive strategy focused on scalable ventures that challenge conventional industry paradigms. With expertise in both engineering and business, he gravitates towards startups poised for disruption, prioritizing innovation as the key to sustained growth. Larkins' unique ability to harness technical knowledge enables him to navigate complex landscapes, forming strategic alliances that amplify value creation across sectors. By fostering collaboration among diverse stakeholders, he enhances his portfolio’s adaptability while aiming for transformative outcomes.
Opportunity identification is at the core of Marc Larkins' investment philosophy, driven by a deep understanding of technology and market dynamics. His entrepreneurial journey informs a proactive strategy focused on scalable ventures that challenge conventional industry paradigms. With expertise in both engineering and business, he gravitates towards startups poised for disruption, prioritizing innovation as the key to sustained growth. Larkins' unique ability to harness technical knowledge enables him to navigate complex landscapes, forming strategic alliances that amplify value creation across sectors. By fostering collaboration among diverse stakeholders, he enhances his portfolio’s adaptability while aiming for transformative outcomes.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
60.69%
Gain -0.36%
Monthly
0.13%
Yearly
1.57%
Drawdown
57.66%
$826.77M
Equity
Holdings
$826.77M
Investment
$621.78M
$30.84M
Profit -$4.61M
Realized
-$174.16M
Unrealized
$204.99M
Dividends
$72.93M
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
-0.36%
Profit
-$4.61M
Win %
31%
This Week
Compared To Last Week
Gain
1.59%
Profit
$12.92M
Win %
31%
This Month
Compared to last month
Gain
1.59%
Profit
$12.92M
Win %
31%
This Year
Compared to last year
Gain
4.94%
Profit
$38.92M
Win %
30%
CBRS Cerebras Systems Inc.
+2.65%
+$303,832.62 
XNCR Xencor Inc.
+1.86%
+$276,782.94 
LAB Standard Biotools Inc.
+1.77%
+$4,305.15 
LEGN Legend Biotech Corporation American Depositary Shares
+1.6%
+$248,449.54 
FATE Fate Therapeutics Inc.
+1.54%
+$135,162.56 
CTNM Contineum Therapeutics, Inc.
+1.44%
+$435,418.06 
PRCT Procept BioRobotics Corporation
+0.05%
+$3,579.39 
ACET Adicet Bio, Inc.
0%
$0 
MGTX MeiraGTx Holdings plc
0%
$0 
PTGX Protagonist Therapeutics Inc.
0%
$0 
VOR Vor Biopharma Inc.
0%
$0 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 67 | Longs Won 15/67 22% | Profit Factor 1.06 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $48.64M |
| Average Win $36.44M | Best Trade (Aug 07) $292.92M | Sharpe Ratio -5.86 |
| Average Loss -$9.92M | Worst Trade (Aug 07) -$191.36M | Z-Score -0.99 (67.94%) |
| Commissions $0 | Avg. Trade Length 2y 3m 6d | Expectancy $460,232.9 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | 48.73% | 60.5% | 68.67% | 75.12% | 80.54% | 85.26% | 89.46% | 93.27% | 96.76% |
| Consecutive Losing Trades | 83 | 75 | 67 | 58 | 50 | 42 | 33 | 25 | 17 | 8 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ACET Adicet Bio, Inc. | 22,779 | $191,799.18 | $208,655.64 | - | $16,856.46 | 8.79% | 0.0 |
| CBRS Cerebras Systems Inc. | 53,586 | $11.84M | $11.79M | - | -$55,193.58 | -0.47% | +2.646% |
| CTNM Contineum Therapeutics, Inc. | 1.98M | $34.85M | $30.66M | - | -$4.2M | -12.04% | +1.441% |
 CVRX CVRx, Inc. | 4.02M | $67.59M | $22.1M | - | -$45.49M | -67.31% | -1.613% |
| FATE Fate Therapeutics Inc. | 3.38M | $200.28M | $8.92M | - | -$191.36M | -95.55% | +1.538% |
| LAB Standard Biotools Inc. | 311,967 | $845,430.57 | $247,639.4 | - | -$597,791.17 | -70.71% | +1.769% |
| LEGN Legend Biotech Corporation American Depositary Shares | 814,586 | $41.19M | $15.77M | - | -$25.42M | -61.72% | +1.601% |
| MGTX MeiraGTx Holdings plc | 6.64M | $62.6M | $83.35M | - | $20.74M | 33.13% | 0.0 |
 NBTX Nanobiotix S.A. American Depositary Shares | 5.62M | $42.35M | $218.09M | - | $175.74M | 414.95% | -2.244% |
 NMRA Neumora Therapeutics, Inc. | 1.85M | $28.85M | $2.96M | - | -$25.89M | -89.74% | -0.621% |
| PRCT Procept BioRobotics Corporation | 357,939 | $13.66M | $6.93M | - | -$6.73M | -49.28% | +0.052% |
| PTGX Protagonist Therapeutics Inc. | 2.45M | $43.4M | $336.32M | - | $292.92M | 674.94% | 0.0 |
 RAPP Rapport Therapeutics Inc. | 1.78M | $41.51M | $73.13M | - | $31.62M | 76.18% | -3.44% |
| VOR Vor Biopharma Inc. | 53,732 | $2.62M | $1.2M | - | -$1.42M | -54.29% | 0.0 |
| XNCR Xencor Inc. | 748,062 | $30.01M | $15.12M | - | -$14.89M | -49.63% | +1.865% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Marc Larkins?
The largest contributions to the portfolio's profits come from the following stocks: Kenvue Inc - $60.17M, Legend Biotech Corporation American Depositary Shares - $15.05M, Rapport Therapeutics Inc - $4.6M, Procept BioRobotics Corporation - $2.23M, and Lyell Immunopharma, Inc - $435,522.33. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Arrowhead Pharmaceuticals Inc - $69.57M, Cue Health Inc - $63.08M, Illumina, Inc - $20.38M, Vor Biopharma Inc - $15.11M, and Adicet Bio, Inc - $4.58M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Marc Larkins's portfolio generate?
The portfolio generates substantial dividend income, with a total of $72.93M earned over time. The largest contributors to dividend income include Kenvue Inc - $72.93M. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Marc Larkins's monthly returns?
Marc Larkins's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Marc Larkins's strategy be considered aggressive or moderate?
Marc Larkins's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Marc Larkins's strategy?
Marc Larkins's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
